Bimodality of gene expression in cancer patient tumors as interpretable biomarkers for drug sensitivity
Ba-alawi, W.; Nair, S. K.; Li, B.; Mammoliti, A.; Smirnov, P.; Mer, A. S.; Penn, L.; Haibe-Kains, B.
Show abstract
Identifying biomarkers predictive of cancer cells response to drug treatment constitutes one of the main challenges in precision oncology. Recent large-scale cancer pharmacogenomic studies have boosted the research for finding predictive biomarkers by profiling thousands of human cancer cell lines at the molecular level and screening them with hundreds of approved drugs and experimental chemical compounds. Many studies have leveraged these data to build predictive models of response using various statistical and machine learning methods. However, a common challenge in these methods is the lack of interpretability as to how they make the predictions and which features were the most associated with response, hindering the clinical translation of these models. To alleviate this issue, we develop a new machine learning pipeline based on the recent LOBICO approach that explores the space of bimodally expressed genes in multiple large in vitro pharmacogenomic studies and builds multivariate, nonlinear, yet interpretable logic-based models predictive of drug response. Using our method, we used a compendium of three of the largest pharmacogenomic data sets to build robust and interpretable models for 101 drugs that span 17 drug classes with high validation rate in independent datasets.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Cancer drug sensitivity prediction from routine histology images 93%
- Generalizing AI-driven Assessment of Immunohistochemistry across Immunostains and Cancer Types: A Universal Immunohistochemistry Analyzer 93%
- Overcoming Resistance to BRAFV600E Inhibition in Melanoma by Deciphering and Targeting Personalized Protein Network Alterations 93%
Similar papers in this journal
- Defining subpopulations of differential drug response to reveal novel target populations 96%
- Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA Damage Response inhibitors 96%
- Stratification and prediction of drug synergy based on target functional similarity 95%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.